In a simulation of adults with type 2 diabetes in France, liraglutide was projected to add 0.25 QALYs of quality-adjusted life expectancy compared with sitagliptin.
In plain wordsIn a computer model for France, liraglutide was projected to give slightly more healthy life years than sitagliptin.
- Peptide
- Liraglutide
- Outcome
- IncreaseProjected quality-adjusted life expectancy versus sitagliptin
- Study
n: not reported in source
Validated computer simulation model of type 2 diabetes- Comparator
- Sitagliptin
- Outcome group
- Healthcare costs and utilization · Whole body
Measurements
- Quality-adjusted life expectancy gain
- 0.25 QALYs
- vs sitagliptin
Source sentences
Liraglutide was associated with an increase in quality-adjusted life expectancy of 0.25 quality-adjusted life years (QALYs) and an increase in mean direct healthcare costs of €2558 per patient compared with sitagliptin.
2 context sentences(design, population, supporting numbers)
The present study aimed to compare the projected long-term clinical and cost implications associated with liraglutide, sitagliptin and glimepiride in patients with type 2 diabetes mellitus failing to achieve glycemic control on metformin monotherapy in France.
Long-term (patient lifetime) projections of clinical outcomes and direct costs (2013 Euros; €) were made using a validated computer simulation model of type 2 diabetes.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.